カナダ - 英語 - Health Canada

aa pharma inc - mefloquine (mefloquine hydrochloride) - tablet - 250mg - mefloquine (mefloquine hydrochloride) 250mg - antimalarials

インド - 英語 - Central Drugs Standard Control Organization

emcure - mefloquine hcl. - tab - 250mg - 2

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - mefloquine hydrochloride, quantity: 274.09 mg (equivalent: mefloquine, qty 250 mg) - tablet, uncoated - excipient ingredients: ammonium alginate; crospovidone; lactose monohydrate; magnesium stearate; microcrystalline cellulose; purified talc; maize starch; poloxamer - malaria treatment: lariam is indicated for the treatment of acute attacks of malaria due to p.falciparum infection resistant to conventional antimalarial drugs. following therapy of mixed p.falciparum/p.vivax malaria with lariam relapse prophylaxis with an 8-aminoquinoline derivative (e.g. primaquine) should be considered in order to eliminate liver forms of p.vivax. malaria prophylaxis: for travellers to countries with documented chloroquine and antifolate combination ( [sulfadoxine/pyrimethamine] / [dapsone/pyrimethamine] ) resistant p.falciparum malaria, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas (between the dusk to dawn period). for travellers hypersensitive to sulphonamides and sulphones, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas, (between the dusk to dawn period) in countries with high level chloroquine-resistant p.fal

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

edgemont pharmaceuticals, llc - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 60 mg - fluoxetine is indicated for the treatment of: the use of maois intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine is contraindicated because of an increased risk of serotonin syndrome. the use of fluoxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.6) and warnings and precautions (5.2)] . starting fluoxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration ( 2.7 ) and warnings and precautions (5.2 )] . the use of fluoxetine is contraindicated with the following: pimozide and thioridazine prolong the qt interval. fluoxetine can increase the levels of pimozide and thioridazine through inhibition of cyp2d6. fluoxetine can also prolong the qt interval. pregnancy category c —fluoxetine should be used during pregnancy

バングラデシュ - 英語 - DGDA (Directorate General of Drug Administration)

edcl (dhaka) - mefloquine - tablet - 250 mg

カナダ - 英語 - Health Canada

hoffmann-la roche limited - mefloquine (mefloquine hydrochloride) - tablet - 250mg - mefloquine (mefloquine hydrochloride) 250mg - antimalarials

シンガポール - 英語 - HSA (Health Sciences Authority)

apotheca marketing pte ltd - mefloquine hcl eqv mefloquine base - tablet - 250 mg - mefloquine hcl eqv mefloquine base 250 mg

シンガポール - 英語 - HSA (Health Sciences Authority)

apex pharma marketing pte. ltd. - mefloquine hcl eqv mefloquine - tablet, film coated - 250 mg - mefloquine hcl eqv mefloquine 250 mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - mefloquine hydrochloride - oral tablet - 250mg

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg - tablet - 250 mg - active: mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg excipient: crospovidone ammonium calcium alginate lactose monohydrate magnesium stearate maize starch microcrystalline cellulose poloxamer purified talc - chemoprophylaxis, therapy and stand-by treatment of malaria. chemoprophylaxis chemoprophylaxis with lariam is recommended for travellers to malarious areas, particularly those travelling to areas where there is a high risk of infection with strains of p. falciparum resistant to other antimalarials. therapy lariam is indicated for the oral treatment of malaria, particularly when caused by strains of p. falciparum resistant to other antimalarials. it may also be used for the treatment of p. vivax and mixed malaria. stand-by treatment lariam is also prescribed as a stand-by medication, to be carried by the traveller and self-administered as an emergency measure for suspected malaria when prompt medical attention is unavailable within 24 hours.